Complexes of HIV-1 RT, NNRTI and RNA/DNA hybrid reveal a structure compatible with RNA degradation

Nature Structural and Molecular Biology

Volumn 20, Issue 2, 2013, Pages 230-236

  Lapkouski, Mikalai ^a   Tian, Lan ^a   Miller, Jennifer T ^b   Le Grice, Stuart F J ^b   Yang, Wei ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS 1 REVERSE TRANSCRIPTASE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RIBONUCLEASE; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DNA RNA HYBRIDIZATION; ENZYME STRUCTURE; PRIORITY JOURNAL;

CRYSTALLIZATION; DNA, VIRAL; HIV-1; MODELS, MOLECULAR; MULTIPROTEIN COMPLEXES; NUCLEIC ACID HETERODUPLEXES; PROTEIN CONFORMATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA STABILITY; RNA, VIRAL; RNA-DIRECTED DNA POLYMERASE; X-RAY DIFFRACTION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84873570106     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.2485     Document Type: Article

References (62)

1. Varmus, H. Reverse transcription. Sci. Am. 257, 56-59, 62-64 (1987).
2. Sarafianos, S.G. et al. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 385, 693-713 (2009).
3. Cihlar, T. & Ray, A.S. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Antiviral Res. 85, 39-58 (2010).
4. de Béthune, M.P. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res. 85, 75-90 (2010).
5. di Marzo Veronese, F. et al. Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science 231, 1289-1291 (1986).
6. Lightfoote, M.M. et al. Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J. Virol. 60, 771-775 (1986).
7. Gilboa, E., Mitra, S.W., Goff, S. & Baltimore, D. A detailed model of reverse transcription and tests of crucial aspects. Cell 18, 93-100 (1979).
8. Whitcomb, J.M. & Hughes, S.H. Retroviral reverse transcription and integration: progress and problems. Annu. Rev. Cell Biol. 8, 275-306 (1992).
9. Nowotny, M., Gaidamakov, S.A., Crouch, R.J. & Yang, W. Crystal structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis. Cell 121, 1005-1016 (2005).
10. Nowotny, M. et al. Structure of human RNase H1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription. Mol. Cell 28, 264-276 (2007).
11. Schultz, S.J. & Champoux, J.J. RNase H activity: structure, specificity, and function in reverse transcription. Virus Res. 134, 86-103 (2008).
12. Shaw-Reid, C.A. et al. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J. Biol. Chem. 278, 2777-2780 (2003).
13. Himmel, D.M. et al. Structure of HIV-1 reverse transcriptase with the inhibitor β-Thujaplicinol bound at the RNase H active site. Structure 17, 1625-1635 (2009).
14. Lansdon, E.B. et al. Structural and binding analysis of pyrimidinol carboxylic acid and N-hydroxy quinazolinedione HIV-1 RNase H inhibitors. Antimicrob. Agents Chemother. 55, 2905-2915 (2011).
15. Steitz, T.A. & Steitz, J.A. A general two-metal-ion mechanism for catalytic RNA. Proc. Natl. Acad. Sci. USA 90, 6498-6502 (1993).
16. Yang, W., Lee, J.Y. & Nowotny, M. Making and breaking nucleic acids: two-Mg2+-ion catalysis and substrate specificity. Mol. Cell 22, 5-13 (2006).
17. Huber, H.E. & Richardson, C.C. Processing of the primer for plus strand DNA synthesis by human immunodeficiency virus 1 reverse transcriptase. J. Biol. Chem. 265, 10565-10573 (1990).
18. Fuentes, G.M., Rodriguez-Rodriguez, L., Fay, P.J. & Bambara, R.A. Use of an oligoribonucleotide containing the polypurine tract sequence as a primer by HIV reverse transcriptase. J. Biol. Chem. 270, 28169-28176 (1995).
19. Gopalakrishnan, V., Peliska, J.A. & Benkovic, S.J. Human immunodeficiency virus type 1 reverse transcriptase: spatial and temporal relationship between the polymerase and RNase H activities. Proc. Natl. Acad. Sci. USA 89, 10763-10767 (1992).
20. Kohlstaedt, L.A., Wang, J., Friedman, J.M., Rice, P.A. & Steitz, T.A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783-1790 (1992).
21. Hopkins, A.L. et al. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 39, 1589-1600 (1996).
22. Ren, J. et al. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure 8, 1089-1094 (2000).
23. Ren, J. & Stammers, D.K. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. Virus Res. 134, 157-170 (2008).
24. Tu, X. et al. Structural basis of HIV-1 resistance to AZT by excision. Nat. Struct. Mol. Biol. 17, 1202-1209 (2010).
25. Jacobo-Molina, A. et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl. Acad. Sci. USA 90, 6320-6324 (1993).
26. Huang, H., Chopra, R., Verdine, G.L. & Harrison, S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282, 1669-1675 (1998).
27. Lansdon, E.B. et al. Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex. J. Mol. Biol. 397, 967-978 (2010).
28. Meyer, P.R., Matsuura, S.E., Mian, A.M., So, A.G. & Scott, W.A. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4, 35-43 (1999).
29. Das, K., Martinez, S.E., Bauman, J.D. & Arnold, E. HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism. Nat. Struct. Mol. Biol. 19, 253-259 (2012).
30. Sarafianos, S.G. et al. Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. EMBO J. 20, 1449-1461 (2001).
31. Beilhartz, G.L. et al. HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA substrate at both DNA polymerase and RNase H active sites: implications for RNase H inhibition. J. Mol. Biol. 388, 462-474 (2009).
32. Hang, J.Q. et al. Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs). Biochem. Biophys. Res. Commun. 352, 341-350 (2007).
33. Radzio, J. & Sluis-Cremer, N. Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Mol. Pharmacol. 73, 601-606 (2008).
34. Shaw-Reid, C.A. et al. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities. Biochemistry 44, 1595-1606 (2005).
35. Delviks-Frankenberry, K.A. et al. HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc. Natl. Acad. Sci. USA 105, 10943-10948 (2008).
36. Delviks-Frankenberry, K.A., Nikolenko, G.N. & Pathak, V.K. The "connection" between HIV drug resistance and RNase H. Viruses 2, 1476-1503 (2010).
37. Peliska, J.A. & Benkovic, S.J. Mechanism of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase. Science 258, 1112-1118 (1992).
38. Ding, J. et al. Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 Å resolution. J. Mol. Biol. 284, 1095-1111 (1998).
39. Hsiou, Y. et al. Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: implications of conformational changes for polymerization and inhibition mechanisms. Structure 4, 853-860 (1996).
40. Rodgers, D.W. et al. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 92, 1222-1226 (1995).
41. Brehm, J.H., Mellors, J.W. & Sluis-Cremer, N. Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry 47, 14020-14027 (2008).
42. Tachedjian, G., Orlova, M., Sarafianos, S.G., Arnold, E. & Goff, S.P. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 98, 7188-7193 (2001).
43. Yap, S.H. et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 4, e335 (2007).
44. Ehteshami, M. et al. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3′-azido-3′- deoxythymidine through both RNase H-dependent and-independent mechanisms. J. Biol. Chem. 283, 22222-22232 (2008).
45. Cameron, C.E., Ghosh, M., Le Grice, S.F. & Benkovic, S.J. Mutations in HIV reverse transcriptase which alter RNase H activity and decrease strand transfer efficiency are suppressed by HIV nucleocapsid protein. Proc. Natl. Acad. Sci. USA 94, 6700-6705 (1997).
46. Chung, S., Miller, J.T., Johnson, B.C., Hughes, S.H. & Le Grice, S.F. Mutagenesis of human immunodeficiency virus reverse transcriptase p51 subunit defines residues contributing to vinylogous urea inhibition of ribonuclease H activity. J. Biol. Chem. 287, 4066-4075 (2012).
47. Perry, J.J., Cotner-Gohara, E., Ellenberger, T. & Tainer, J.A. Structural dynamics in DNA damage signaling and repair. Curr. Opin. Struct. Biol. 20, 283-294 (2010).
48. Rambo, R.P. & Tainer, J.A. Bridging the solution divide: comprehensive structural analyses of dynamic RNA, DNA, and protein assemblies by small-angle X-ray scattering. Curr. Opin. Struct. Biol. 20, 128-137 (2010).
49. Gerondelis, P. et al. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end-and DNA 3′-end-directed RNase H activities. J. Virol. 73, 5803-5813 (1999).
50. Wendeler, M. et al. Vinylogous ureas as a novel class of inhibitors of reverse transcriptase-associated ribonuclease H activity. ACS Chem. Biol. 3, 635-644 (2008).
51. Chung, S. et al. Structure-activity analysis of vinylogous urea inhibitors of human immunodeficiency virus-encoded ribonuclease H. Antimicrob. Agents Chemother. 54, 3913-3921 (2010).
52. Tuske, S. et al. Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat. Struct. Mol. Biol. 11, 469-474 (2004).
53. Le Grice, S.F., Cameron, C.E. & Benkovic, S.J. Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Methods Enzymol. 262, 130-144 (1995).
54. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
55. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
56. CCP4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994).
57. Adams, P.D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
58. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
59. Cohen, G.H. ALIGN: a program to superimpose protein coordinates, accounting for insertions and deletions. J. Appl. Crystallogr. 30, 1160-1161 (1997).
60. Richards, F.M. & Kundrot, C.E. Identification of structural motifs from protein coordinate data: secondary structure and first-level supersecondary structure. Proteins 3, 71-84 (1988).
61. Lu, X.J. & Olson, W.K. 3DNA: a versatile, integrated software system for the analysis, rebuilding and visualization of three-dimensional nucleic-acid structures. Nat. Protoc. 3, 1213-1227 (2008).
62. Lavery, R., Moakher, M., Maddocks, J.H., Petkeviciute, D. & Zakrzewska, K. Conformational analysis of nucleic acids revisited: Curves. Nucleic Acids Res. 37, 5917-5929 (2009).